---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-055666"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T17:10:53.766701+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# XOMA Royalty reports Q4/FY2024 revenue $28.5M, net loss $13.8M; portfolio doubled to 120+ assets

## Summary
- Total revenue $8.7M Q4, $28.5M FY2024 (vs $1.8M and $4.8M in 2023); net loss $4.0M Q4, $13.8M FY2024.
- Cash and equivalents $106.4M at Dec 31, 2024; cash receipts totaled $46.3M in FY2024.
- Doubled royalty portfolio to over 120 assets via five 2024 transactions: Twist ($15M), Daré ($22M), Talphera ($8M), Kinnate ($2.5879/sh + CVR), Pulmokine ($20M).
- FDA approvals for Day One's OJEMDA and Zevra's MIPLYFFA; milestone payments received from both.
- Non-cash credit losses $30.9M FY2024 (Agenus, Aronora, Talphera); management sees path to cash flow positive from royalties alone in 2025.

## SEC filing metadata
- accession: 0001193125-25-055666
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312525055666/0001193125-25-055666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312525055666/d903231d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-055666
- JSON: https://secwatch.observer/filing/0001193125-25-055666.json
- Plain text: https://secwatch.observer/filing/0001193125-25-055666.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.